Search results for "BREAST"

showing 10 items of 1871 documents

Breastfeeding Practices Influence the Breast Milk Microbiota Depending on Pre-Gestational Maternal BMI and Weight Gain over Pregnancy

2021

Breastfeeding is critical for adequate neonatal microbial and immune system development affecting neonate health outcomes in the short and long term. There is a great interest in ascertaining which are the maternal factors contributing to the milk microbiota and the potential relevance for the developing infant. Thus, our study aimed to characterize the effect of mixed and exclusive breastfeeding practices on the milk microbiota and to determine the impact of pre-pregnancy body mass index (BMI) and weight gain over pregnancy on its composition. Breast milk samples from 136 healthy women were collected within the first month post-partum and milk microbiota profiling was analyzed by 16S rRNA …

0301 basic medicineAdultbreastfeeding030106 microbiologyBreastfeedingBreastfeedingbody mass indexBreast milkHealth outcomesArticle03 medical and health sciencesfluids and secretionsEnvironmental healthmedicineHumansTX341-641Body mass indexBifidobacterium2. Zero hungerPregnancyNutrition and DieteticsbiologyBacteriaMilk Humanbusiness.industryNutrition. Foods and food supplyMicrobiotabiology.organism_classificationmedicine.diseaseGestational Weight Gain3. Good health030104 developmental biologyBreast FeedingGestationFemalemedicine.symptombusinessBody mass indexWeight gainFood ScienceNutrients
researchProduct

Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer

2019

Research question: Does ovarian stimulation for oocyte vitrification affect disease-free survival and overall survival rates in women with early breast cancer? Design: This cohort study included 259 patients with early breast cancer; 148 patients underwent ovarian stimulation, whereas 111 patients did not. Patients were treated between January 2008 and December 2016. To calculate the disease-free survival time and overall survival rate, the time of definitive surgery was defined as the starting point. The follow-up was conducted up to 5 years. Results: Exposed and non-exposed groups were comparable in tumour, node and metastases classification, Nottingham grade, hormonal receptor status, tu…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentDisease-free survivalStimulationBreast NeoplasmsKaplan-Meier EstimateOverall survival rateGastroenterologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerBreast cancerOvulation InductionInternal medicinemedicineHumansFertility preservationProspective StudiesStage (cooking)Neoplasm MetastasisFertility preservationRetrospective StudiesCryopreservation030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyFertility PreservationHistologymedicine.diseaseVitrificationConfidence intervalSurvival Rate030104 developmental biologyTreatment OutcomeReproductive MedicineOocytesFemaleOvarian stimulationNeoplasm Recurrence LocalbusinessDevelopmental BiologyCohort studyHormoneFollow-Up Studies
researchProduct

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer…

2016

Summary Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel after surgery. Here, we report 5-year progression-free survival, disease-free survival, and safety. Methods In this multicentre, open-label, phase 2 randomised trial in hospitals and medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage HER2-positive breast cancer were randomly assigned (1:1:1:1) to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus do…

0301 basic medicineAdultmedicine.medical_specialtyTime FactorsAdolescentReceptor ErbB-2PopulationAntibodies Monoclonal HumanizedGastroenterologyGroup B03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overeducation.field_of_studybusiness.industryMiddle AgedTrastuzumabmedicine.diseasePrognosisNeoadjuvant TherapySurgerySurvival Rate030104 developmental biologyOncologyDocetaxelTolerabilityChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleInflammatory Breast NeoplasmsPertuzumabNeoplasm Recurrence LocalbusinessFebrile neutropeniamedicine.drugEpirubicinFollow-Up StudiesThe Lancet. Oncology
researchProduct

Raman Spectroscopic Measurements of Dermal Carotenoids in Breast Cancer Operated Patients Provide Evidence for the Positive Impact of a Dietary Regim…

2015

Dermal carotenoids are a feasible marker of the body antioxidative network and may reveal a moderate to severe imbalance of the redox status, thereby providing indication of individual oxidative stress. In this work noninvasive Resonance Raman Spectroscopy (RRS) measurements of skin carotenoids (skin carotenoid score (SCS)) were used to provide indications of individual oxidative stress, each year for five years, in 71 breast cancer (BC) patients at high risk of recurrence. Patients’ SCS has been correlated with parameters relevant to BC risk, waist circumference (WC), and body mass index (BMI), in the aim of monitoring the effect of a dietary regimen intended to positively affect BC risk f…

0301 basic medicineAgingmedicine.medical_specialtyPathologyWaistTime FactorsArticle SubjectBreast Neoplasmsmedicine.disease_causeSpectrum Analysis RamanBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerInternal medicineVegetablesmedicineantioxidants skin carotenoids oxidative stress breast cancer Raman spectroscopyHumanslcsh:QH573-671Carotenoidchemistry.chemical_classification030109 nutrition & dieteticsAnthropometryintegumentary systembusiness.industrylcsh:Cytologyfood and beveragesCell BiologyGeneral MedicineAnthropometrymedicine.diseasePrognosisCarotenoidsLycopeneDietOxidative Stresschemistry030220 oncology & carcinogenesisFruitFemalebusinessDietary regimenBody mass indexOxidative stressResearch ArticleOxidative Medicine and Cellular Longevity
researchProduct

Sodium functions as a negative allosteric modulator of the oxytocin receptor

2017

Abstract The oxytocin receptor, a class A G protein coupled receptor (GPCR), is essentially involved in the physiology of reproduction. Two parameters are crucially important to support high-affinity agonist binding of the receptor: Mg2+ and cholesterol, both acting as positive modulators. Using displacement assays with a high-affinity fluorescent antagonist (OTAN-A647), we now show that sodium functions as a negative allosteric modulator of the oxytocin receptor. In membranes from HEK293 cells stably expressing the oxytocin receptor, oxytocin binding occurred with about 15-fold lower affinity when sodium chloride was increased from 0 to 300 mM, whereas antagonist binding remained largely u…

0301 basic medicineAgonistAllosteric modulatormedicine.drug_classSodiumBiophysicschemistry.chemical_elementBreast NeoplasmsSodium ChlorideOxytocinBiochemistryPotassium Chloride03 medical and health sciencesAllosteric RegulationCell Line TumormedicineHumansAmino Acid SequenceReceptorFluorescent DyesG protein-coupled receptorDose-Response Relationship DrugSequence Homology Amino AcidChemistryCell MembraneCell BiologyOxytocin receptorRecombinant ProteinsCell biologyCholesterolHEK293 Cells030104 developmental biologyOxytocinReceptors OxytocinMutagenesis Site-DirectedCalciumFemaleSequence Alignmenthormones hormone substitutes and hormone antagonistsIntracellularProtein Bindingmedicine.drugBiochimica et Biophysica Acta (BBA) - Biomembranes
researchProduct

A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Can…

2017

AbstractSomatic mutations of the Estrogen Receptor α (ERα) occur with an up to 40% incidence in ER sensitive breast cancer (BC) patients undergoing prolonged endocrine treatments. These polymorphisms are implicated in acquired resistance, disease relapse, and increased mortality rates, hence representing a current major clinical challenge. Here, multi-microseconds (12.5 µs) molecular dynamics simulations revealed that recurrent ERα polymorphisms (i. e. L536Q, Y537S, Y537N, D538G) (mERα) are constitutively active in their apo form and that they prompt the selection of an agonist (active)-like conformation even upon antagonists binding. Interestingly, our simulations rationalize, for the firs…

0301 basic medicineAgonistModels MolecularBreast cancerComputational chemistryMolecular dynamicsSomatic cellmedicine.drug_classlcsh:MedicineEstrogen receptorBreast Neoplasms-Molecular Dynamics SimulationPolymorphism Single NucleotideArticleProtein Structure SecondaryEstrogen Receptor Antagonists03 medical and health sciences0302 clinical medicineBreast cancermedicineEndocrine systemHumanslcsh:ScienceMultidisciplinarybusiness.industrylcsh:REstrogen Receptor alphamedicine.diseaseEstrogen Receptor Antagonist030104 developmental biologySelective estrogen receptor modulator030220 oncology & carcinogenesisCancer researchlcsh:QFemaleEstrogen Receptor AntagonistsbusinessEstrogen receptor alphaBreast NeoplasmHuman
researchProduct

Expression of Alpha-Enolase (ENO1), Myc Promoter-Binding Protein-1 (MBP-1) and Matrix Metalloproteinases (MMP-2 and MMP-9) Reflect the Nature and Agg…

2019

Breast cancer is a complex and heterogeneous disease: Several molecular alterations cause cell proliferation and the acquisition of an invasive phenotype. Extracellular matrix (ECM) is considered essential for sustaining tumor growth and matrix metalloproteinases (MMPs) have been identified as drivers of many aspects of the tumor phenotype. Mounting evidence indicates that both &alpha

0301 basic medicineAlpha-enolaseENO1Kaplan-Meier EstimateMatrix metalloproteinasemedicine.disease_causeMetastasisExtracellular matrixlcsh:Chemistry0302 clinical medicineSettore BIO/06 - Anatomia Comparata E Citologialcsh:QH301-705.5SpectroscopybiologyMMP-2General MedicineComputer Science ApplicationsDNA-Binding ProteinsGene Expression Regulation NeoplasticMatrix Metalloproteinase 9030220 oncology & carcinogenesisDisease ProgressionMatrix Metalloproteinase 2FemaleMMP-9Breast NeoplasmsCatalysisArticleInorganic Chemistry03 medical and health sciencesBreast cancerbreast cancerCell Line TumormedicineBiomarkers TumorHumansPhysical and Theoretical ChemistryMBP-1Molecular BiologyCell ProliferationTumor Suppressor ProteinsOrganic ChemistryCancermedicine.diseaseSettore BIO/18 - Genetica030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Phosphopyruvate HydrataseCancer cellbiology.proteinCancer researchCarcinogenesisInternational Journal of Molecular Sciences
researchProduct

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

2016

// Daniele Fanale 1, * , Valeria Amodeo 1, * , Viviana Bazan 1, * , Lavinia Insalaco 1 , Lorena Incorvaia 1 , Nadia Barraco 1 , Marta Castiglia 1 , Sergio Rizzo 1 , Daniele Santini 2 , Antonio Giordano 3 , Sergio Castorina 4, 5, # , Antonio Russo 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 University Campus Bio-Medico, Department of Medical Oncology, Rome, Italy 3 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 4 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 5 Department of Biomedic…

0301 basic medicineAntineoplastic AgentsBreast NeoplasmsBioinformatics03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancermicroRNAmedicineHumansZoledronic acidPI3K/AKT/mTOR pathwaybone metastasisBone Density Conservation AgentsDiphosphonatesMicroarray analysibusiness.industryGene Expression ProfilingImidazolesBone metastasisMicroRNA Expression Profilemedicine.diseaseActin cytoskeletonMolecular medicineBone metastasis; Breast cancer; Microarray analysis; miRNA expression profile; Zoledronic acid; Oncology030104 developmental biologyZoledronic acidOncologyBone metastasi030220 oncology & carcinogenesisMCF-7 CellsCancer researchmiRNA expression profilemicroarray analysisTranscriptomebusinessResearch Papermedicine.drug
researchProduct

Green Tea Catechins Induce Inhibition of PTP1B Phosphatase in Breast Cancer Cells with Potent Anti-Cancer Properties: In Vitro Assay, Molecular Docki…

2020

The catechins derived from green tea possess antioxidant activity and may have a potentially anticancer effect. PTP1B is tyrosine phosphatase that is oxidative stress regulated and is involved with prooncogenic pathways leading to the formation of a.o. breast cancer. Here, we present the effect of selected green tea catechins on enzymatic activity of PTP1B phosphatase and viability of MCF-7 breast cancer cells. We showed also the computational analysis of the most effective catechin binding with a PTP1B molecule. We observed that epigallocatechin, epigallocatechin gallate, epicatechin, and epicatechin gallate may decrease enzymatic activity of PTP1B phosphatase and viability of MCF-7 cells.…

0301 basic medicineAntioxidantPhysiologymedicine.medical_treatmentClinical BiochemistryPhosphataseProtein tyrosine phosphataseEpigallocatechin gallateBiochemistrycomplex mixturesArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicinebreast cancermedicineheterocyclic compoundsViability assayMolecular Biologyepigallocatechinprotein tyrosine phosphatase inhibitorChemistrylcsh:RM1-950food and beveragesPTP1BCell BiologyCatechin bindingIn vitro030104 developmental biologyEpicatechin gallatelcsh:Therapeutics. PharmacologyBiochemistrySettore CHIM/03 - Chimica Generale E Inorganica030220 oncology & carcinogenesissense organshormones hormone substitutes and hormone antagonistsgreen tea catechinsAntioxidants
researchProduct

Safe neoadjuvant trastuzumab-based treatment in HER2 + inflammatory early breast cancer in a glucose 6-phosphate dehydrogenase-deficient postmenopaus…

2019

Introduction Glucose 6-phosphate dehydrogenase (G6PD) is a basic antioxidant pathway for erythrocytes, being its deficiency the most common gene mutation worldwide. As breast cancer is one of the most frequent tumors, many of these patients may present with G6PD deficiency prior treatment without notice. Case report We present the case of a woman deficient for G6PD with the diagnosis of Stage IIIB (cT4d cN1 cM0) HER2-enriched early breast cancer. Management and outcome The patient underwent neoadjuvance with trastuzumab and anthracycline-free chemotherapy, based on docetaxel (75 mg/m2, 120 mg) and carboplatin (AUC 5, 560 mg). She did not present hemolytic crisis and no blood transfusions we…

0301 basic medicineAntioxidantReceptor ErbB-2medicine.medical_treatmentCommon geneBreast NeoplasmsDehydrogenasemedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabmedicineHumansGlucose-6-phosphate dehydrogenasePharmacology (medical)skin and connective tissue diseasesAgedEarly breast cancerMutationbusiness.industryTrastuzumabmedicine.diseaseNeoadjuvant TherapyPostmenopauseGlucosephosphate Dehydrogenase DeficiencyTreatment Outcome030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisCancer researchFemalebusinessmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct